Endostatin Protein Market

Key data points: Market size in 2027 = $602.2 million and 2035 = $1027 million, growth forecast = 7.5% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in endostatin protein market to 2035 by type (natural endostatin and recombinant endostatin), application (medical and pharmaceuticals), and region (North America, Europe, Asia Pacific, and the Rest of the World) Endostatin Protein Market The future of the global endostatin protein market looks promising with opportunities in the medical and pharmaceutical markets. The global endostatin protein market is expected to reach an estimated $1027 million by 2035 from $602.2 million in 2027 with a CAGR of 7.5% from 2027 to 2035. The major drivers for this market are the increasing demand for targeted cancer therapies, the rising use in biomedical & clinical research, and the growing development of recombinant protein technologies. • Lucintel forecasts that, within the type category, recombinant endostatin is expected to witness higher growth over the forecast period due to rise in the use of endostatin in oncology and the subsequent increase in investment in the manufacture of pharmaceuticals. • Within the application category, pharmaceuticals is expected to witness higher growth over the forecast period due to increasing demand and use of endostatin in the pharmaceutical industry. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to advantages of utilizing endostatin in cancer treatment. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Endostatin Protein Market The market for Endostatin, based on Lucintel’s analysis, is expected to shift beyond 2027 to the use of Endostatin as a biomarker in cancer. Additionally, the market is expected to shift to the use of Endostatin in combination with other cancer therapies and to the manufacturability of such products. It is expected that combination therapies, improvements in the engineering of biologics, and strategic clinical trial design will position other proteins to be more amenable to commercialization than Endostatin. • Combination Oncology: It is expected that the combination of Endostatin with other chemotherapy or targeted agents will be a dominant theme in clinical development from 2025 to 2027. The only endostatin-based product that is commercially available is Endostar, which is approved in China. Other combinations with Endostatin are expected to yield a broader range of indications in the mid-to-long term. • Biomarker Selection: From a commercial development perspective, prioritization of endpoints relating to tumor vasculature and angiogenic pathways in patient sub-populations reflect an emphasis on marker-based selection and shift towards precision-oncology. • Protein Engineering: Endostatin remains a biologic with a relatively short half-life. Continued engineering to improve its stability, exposure and other formulation features will improve clinical utility. Further improvements in molecular engineering of Endostatin may enhance its commercial utility. • Manufacturing. In addition to the market demands described previously, by 2025, biologics developers will have to demonstrate the purity of their products. In the absence of such evidence, developers will have a hard time launching biologics in the market. Until then, developers will have to rely on processes and technology to produce biologics at large scale. Price and supply will be the main factors for biologics developers to forge partnerships by 2030. • Regional Markets: Chinese developers will be the first to commercialize biologics based on endostatin; thus, they will be the main reference for the rest of the developers. Unlike Chinese developers, others will adopt licensing and joint venture models for biologics, especially for oncology products. Developers will be less likely to build stand-alone biologics facilities. The Rest of the World will adopt biologics based on endostatin if comparing evidence and data warrant such actions, and if regulatory agencies and health care systems align their policies and strategies. It is anticipated that adoption of endostatin-based biologics will depend more on clinical evidence and differentiation. Other factors that will influence adoption will be manufacturing costs and economics. Evidence generated by China will help elevate endostatin-based biologics in the Rest of the World. Most biologics based on endostatin will be confined to research. Survival and quality of life-improving biologics will be prioritized by pharmaceutical companies. Recent Developments in the Endostatin Protein Market Endostatin protein market is clinically narrow but product innovations are forthcoming from China. In the period 2025 to 2027, market activity is likely to include improvement in product formulations and manufacturing, and biomarker based trials. From Lucintel’s perspective, product innovations are likely to be few but significant. • Biomarker-based Combination Trials: The majority of ongoing trials of endostatin evaluate its efficacy when combined with various chemotherapies and/or immune checkpoint inhibitors. As of January 2025, over 20 such trials were listed on ClinicalTrials.gov for the year 2025. Endostatin could improve the effectiveness of chemotherapy and/or checkpoint inhibitor based treatments. • Formulation: The major constraint in endostatin based therapies is the short-lived and unpredictable presence of the drug in the body. One solution to this constraint would be to develop endostatin based therapies that have a long-lasting and/or unrestricted presence in the body. • Regional Focus: Endostar, the only commercially available endostatin based product, is distributed by various companies in China. Endostar was approved in China in 2005, and currently is available in a 15mg/ml dose. Hence, development and availability of new endostatin based products would have a little impact on the overall market if China does not remove its restrictions on reimbursement for Endostar. • Tighter Process Control: Stringent regulations governing biologics are forcing rHEP and other recombinant protein manufacturers to invest in improved process control and cold-chain logistics, as well as more robust comparability testing. In February 2025, China’s NMPA updated its regulation on the release of drug lots. More consistent drug batches may lead to higher acceptance rates in Asian markets. • Coordinated Development Partnerships: Translational studies combining the suppression of angiogenesis and other pathways in cancer are of great interest to the biotechnology sector. According to a 2025 report by the National Cancer Institute, over 2,000 clinical studies of cancer immunotherapy are ongoing. Partnerships focused on endostatin are expected to raise investment capital. However, positive results will likely have to come in combination with other agents. Given the presence of competing therapies, the potential market for endostatin is likely to be limited. There may be significant potential in combination therapies where predictive biomarkers and other improvements in strategy and implementation enable better control over dosing. Strategic Growth Opportunities in the Endostatin Protein Market Endostatin is expected to be commercially available in the coming years with the advancement of related oncology pipelines. It is expected that from 2024 to 2026, the availability of clinical data and continued emphasis on cancer treatment would create additional market potential beyond its initial market. Beyond its current use, Lucintel anticipates the market potential in combination with other biologics and specific therapies in oncology. • Combination Therapies: From a business potential point of view, combination therapies involving endostatin with other immunotherapies and/or chemotherapies is expected to gain market traction. It is anticipated that in the marketplace, differentiating combinations of biologics and/or oncology therapies would gain market potential faster than other single therapy biologics. • Next-Generation Biologics: There is a potential for endostatin to be formulated in a manner that improves its physical stability and/or increases its half-life. It is expected that in the next 3-5 years, biologics would gain market potential faster when compared with other classes of drugs. • Other Indications: Given the relevance of angiogenesis in solid tumors, endostatin may gain market potential in other tumors including ovarian and liver cancers. • Regional Licensing and Local Manufacturing To Improve Drug Access: Regional licenses and on-site manufacturing improve drug access. The National Medical Products Administration of China reported more than 2,000 innovative drug approvals in April 2025. Barriers such as supply and distribution will be reduced with local partnerships. • Growth of Recombinant Protein Manufacturing and Contract Services: Recombinant proteins will be produced via bioprocessing and contract manufacturing. As of February 2025, the U.S. FDA biologics list included 700 entries. Manufacturers will gain income through technology and quality assurance transfers as well as fill-finish services. The first barrier for market entry is clinical. Once this is achieved, the market will be largely dominated by the suppliers that create recombinant protein endostatin and fully characterize it for various cancers. Potency combined with real-world evidence will create a strong value proposition for endostatin. The most favorable markets are likely to be regions with a high incidence of cancer and a compelling unmet need. Endostatin Protein Market Drivers and Challenges Positive and negative changes in the global economy, advances in technology and new trends in health and care together with new regulations affect the market for endostatin protein. More limited market access and reimbursement inhibit market growth, while advancements in protein engineering and anti-angiogenic research and development as well as a greater focus on oncology help establish the market. According to Lucintel, the key driver for market growth is innovation. The factors responsible for driving this market include: • Greater Oncology Focus: As the number of people diagnosed with cancer continues to increase, so does the need for treatment to inhibit the formation of new blood vessels by tumors. If current trends continue, it is likely that demand for endostatin and similar drugs will increase. In 2022 the World Health Organization (WHO) estimated there were approximately 20 million new cases of cancer diagnosed worldwide each year and that figure is expected to increase in the coming years. • Increased Product Development: Ongoing research into methodologies for the expression, purification, and delivery of recombinant proteins continues to enhance endostatin-based products. Emerging advances in the field of artificial intelligence and its application in drug discovery could also augment the development of endostatin-related products. Within the next 3 to 5 years, expect further advances in the field of endostatin-based product development. • Expanding Clinical Research: Research focused on the use of anti-angiogenic proteins, including endostatin, is ongoing at academic and medical institutions worldwide. Current data reflect an increasing trend in the overall volume of clinical research. Within the next 3 to 5 years, expect ongoing clinical research to define the role of endostatin and facilitate collaborations to further develop the drug. • Improved Regulatory and Funding Environment: Ongoing research in biologics has resulted in thousands of new drug development initiatives, including orphan drugs. Regulatory pathways for innovative drugs and biologics have been established. Improved guidelines for endostatin-related products may be developed to facilitate commercialization. • Efficiencies in Manufacturing: Biologics manufacturing continues to evolve. Improvements in the production of recombinant proteins and cell culture, and automation of manufacturing processes, are gaining traction and will likely reduce the cost of manufacture and enhance consistency of biologics. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) stated in April 2025 that the biologics of the future will rely on the application of the latest manufacturing technologies. It is expected that biologics manufacturing will continue to evolve, improving the affordability and reliability of large-scale manufacturing. This should reduce the risks associated with supplying biologics and encourage sponsors to develop larger clinical programs. The challenges facing this market include: • Reliance on Clinical Data: The main obstacle for endostatin is the lack of modern, large, high-quality clinical trials. The results of clinical studies supported by the National Cancer Institute will be useful. They will likely shape the future of cancer research and therapies. Endostatin may benefit from such advances. The competitive environment will likely promote the development of more effective therapies and ease the concerns of potential investors. • Manufacturing and Distribution Challenges: The final barrier for endostatin relates to the manufacture and distribution of recombinant proteins. The limitations associated with the transportation and storage of recombinant proteins, as well as their potential to induce an immune response, may discourage further research and development. The challenges associated with manufacturing proteins may encourage competitors to research and develop more stable proteins. • Competitive Pressure: The established anti-angiogenic drugs and immunotherapies as well as biosimilities and other, more, personalized drugs will compete with endostatin products. Furthermore, the value and price-related reimbursement issues will delay market access to endostatin-based products. Products will also likely face restrictive market access due to limited evidence related to their cost-effectiveness. New drug development in general as well as endostatin product development is positively influenced by the growth in personalized medicine, new clinical and regulatory frameworks as well as the progress in biopharmaceutical manufacturing. However, these innovations and efforts will not change that endostatin products, similar to other personalized medicines, will only be fully reimbursed after positive clinical outcome data have been generated and sufficient evidence on their clinical value has been compiled. During the next several years, most of the innovations will come from the industry. However, in the more distant future, equally important advances will happen as a result of cooperations and alliances between pharmaceutical and biotech companies as well as between research, manufacturing, and health care services. The most promising markets will likely be developed and established by research institutions and biopharmaceutical companies. List of Endostatin Protein Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies endostatin protein market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the endostatin protein market companies profiled in this report include- • Sigma-Aldrich • R&D Systems • Prospec • Innovative Research • Novus Biologicals Endostatin Protein Market by Segment The study includes a forecast for the global endostatin protein market by type, application, and region. Endostatin Protein Market by Type [Value ($M) from 2019 to 2035]: • Natural Endostatin • Recombinant Endostatin Endostatin Protein Market by Application [Value ($M) from 2019 to 2035]: • Medical • Pharmaceuticals Endostatin Protein Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Endostatin Protein Market In comparison to regulatory and pharmaceutical company strategy changes, and major technological advances, the introduction of new products for dydrogesterone is expected to be comparatively less. Around 2025-2027, various companies would be seeking to get their products launched in the markets of various countries of Asia and Europe. As per a study done by Lucintel, in such a scenario, the most likely major changes would be regulatory and strategy changes by pharmaceutical companies. • United States: Right now, the FDA has not approved any use of dydrogesterone. However, some brands of progesterone-only products have been approved by the FDA. The FDA’s website did not show approval of dydrogesterone in 2025. Therefore, companies which wish to sell dydrogesterone in the US, would need to secure approval of the FDA and evaluate the compliance of their manufacturing facility with the requirements of the FDA. • China: Several products which contain dydrogesterone have been approved in China. One of such products is Duphaston of Abbott. Other pharmaceutical companies which wish to sell dydrogesterone products in China, would need to comply with the current laws and washmere (i.e. obtain marketing authorization and comply with the regulatory requirements). • Germany: German pharmaceutical companies involved in the centralized European drug system must take necessary actions to ensure that their drug suppliers adhere to the EU pharmacovigilance and GMP. The ongoing work program of the EMA (2025-2027) provides an idea regarding the future of EU GMP. German pharmaceutical companies can continue to take part in the tenders awarded by various EU member states, and rely on imports of pharmaceutical products to meet the requirements of such tenders. • India: Abbott India has continued to market Duphaston in 2025. Other local pharmaceutical companies also manufacture and market generic dydrogesterone in India. Abbott India reported a turnover of 60.91 billion INR in the financial year 2025. • Japan: It is expected that the major competitors of dydrogesterone in Japan also undertake substantial capital expenditures in 2025. However, no such investments were made by the manufacturers of dydrogesterone. The Japanese health authority Features of the Global Endostatin Protein Market Market Size Estimates: endostatin protein market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: endostatin protein market size by type, application, and region in terms of value ($B). Regional Analysis: endostatin protein market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the endostatin protein market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the endostatin protein market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the endostatin protein market by type (natural endostatin and recombinant endostatin), application (medical and pharmaceuticals), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?